A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
Clinical trial NCT04595409 · COMPLETED
Trial details
- NCT number
- NCT04595409
- Sponsor
- Bioeq GmbH
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-09
- Primary completion
- 2021-06-07
- Enrollment
- 392
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.